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Hormone replacement therapy (HRT) has become increasingly
popular during the last decades. As yet the overall health benefit of
HRT use is not known. An increased risk of breast and endometrial
cancer has been seen (Kelsey and Whittemore, 1994), while there
is a lower risk of osteoporosis (Genazzani and Gambacciani,
1999). A lower risk of cardiovascular disease and cognitive disor-
ders as dementia has been hypothesized but is yet not supported
by intervention studies (Genazzani and Gambacciani, 1999;
Torgerson and Reid, 1999). The risk of endometrial cancer has
been seen mainly for unopposed estrogen medication while the
addition of progestins has normalised the risk (Pike and Ross,
2000). A higher risk of breast cancer has not been seen in all
studies but recent studies, mainly reviewed in the collaborative
meta-analysis, have demonstrated an increased risk (Collaborative
Group on Hormonal Factors in Breast Cancer, 1997). Only a few
cohort investigations exist (Mills et al, 1989; Hunt et al, 1990;
Risch and Howe, 1994; Colditz et al, 1995; Persson, 1996; Lando
et al, 1999; Schairer et al, 2000) and most studies find an increased
incidence or mortality of breast cancer (Mills et al, 1989; Hunt
et al, 1990; Risch and Howe, 1994; Colditz et al, 1995; Persson,
1996; Schairer et al, 2000). However there is still controversy
about how high the risk is and whether it is transient or increasing
with exposure and follow-up time. Recent studies have also
suggested that preparations containing oestrogen alone do not
increase the risk substantially while preparations containing both
oestrogens and progestins do increase the risk (Magnusson et al,
1999; Ross et al, 2000; Schairer et al, 2000). 
Some studies have suggested that the tumour biology of breast
cancer associated with HRT use is favourable (Brinton et al, 1986;
Magnusson et al, 1996; Holli et al, 1998; O’Connor et al, 1998)
and that the prognosis is better than for other women diagnosed at
a similar age (Jernström et al, 1999; Schairer et al, 1999). It has
also been suggested that there is an increase in the incidence of
lobular breast cancer but not of ductal breast carcinomas in the US
and that this increase could be due to HRT use (Li et al, 2000a,b).
The risk relationship requires further study with longer follow up,
less possibility of recall bias, and with assessment of overall
tumour incidence and mortality as well as the risk and mortality
from other diseases. We have examined the risk for breast cancer
in a cohort study in relation to time of exposure to HRT and family
history of breast cancer. 
MATERIAL AND METHODS 
40 000 women aged 25–65 years were randomly selected from the
general population of the South Swedish Health Care Region and
invited to take part in a standardized written interview of risk
factors of malignant melanoma and breast cancer. No woman had
a past history of malignancy. The interviews were performed
between 1990–92. 1000 women from each birth year between age
25–65 were invited to participate in the study. About 74% of all
women (n = 29 508) accepted to participate and participation was
well balanced between the different age groups. In the different
age groups 2803 women were finally included in age group 25–29,
3970 in age group 30–34, 3616 women in age group 35–39, 3639
in age group 40–44, 3647 in age group 45–49, 3658 in age group
50–54, 3495 in age group 55–59 and 4670 women in age
group 60–65. 
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The questionnaire included among other things questions
about age at menarche, parity, age at first full-term pregnancy, age
at menopause, type of menopause, oral contraceptive use
(starting age, duration of use, brand use, age at last use),
HRT use (starting age, duration of use, brand use, age at last
use), family history of cancer/breast cancer, sun bathing habits,
constitutional factors and alcohol and smoking habits. 
With the help of the unique person identification number the
vital status and the cancer incidence up to age 75 of these referents
were then followed from the time of interview onward in the popu-
lation based Census Registry, Cause of Death Registry and
Swedish Cancer Registry (South Swedish Regional and National
Swedish Tumour Registry). Each individual could have had more
than one tumour registered. Observed versus expected number of
tumours were then calculated using reference data from the
southern health care region. The vital status was determined up to
1 January 2000. No subjects were lost to follow up. 5 women
emmigrated and 589 women died during the follow-up time.
Cause-specific standardized incidence ratios (SIRs) and 95%
confidence intervals (CIs) were calculated. P values were calcu-
lated by using the poisson distribution or the χ 2 distribution if the
expected values were greater than 10. The term ‘significant’ refers
to P < 0.05. All tests are 2-tailed. 
In Cox regression models the risk for breast cancer was
modelled within the cohort while adjusting for possible
confounding factors. 
RESULTS 
At the end of the follow up in December 1999, the cohort consti-
tuted 226 611 person years. The median follow up time was 7.6
years. A total of 1145 malignant tumours were seen and 1166.6
were expected (SIR = 0.98, 95% CI 0.93–1.04). Slightly more
breast cancer cases (434) were seen than expected (387.69) (SIR =
1.12, 95% CI 1.02–1.23). About 3663 women had ever used HRT.
Ever use of HRT was associated with a significantly elevated risk
for breast cancer (SIR = 1.35, 95% CI 1.09–1.64) compared with
never use (SIR = 1.07, 95% CI 0.96–1.19). With increasing dura-
tion of use SIR increased (see Table 1) so a duration of HRT use
between 48–120 months yielded a SIR = 1.92, 95% CI 1.32–2.70.
There was no significant interaction between family history of
breast cancer and HRT (see Table 2). 
In a Cox regression model (Table 3) time to breast cancer in
relation to duration of HRT use was analysed adjusting for age at
menarche, age at menopause, age at first full term pregnancy,
parity and age at diagnosis. A significantly higher risk was seen
for longer duration of HRT use (> 48 months) compared with
never users. 
Restricting the regression analysis to women above 45 years 
of age and who had a natural menopause gave similar results
(Table 4) 
The risk of breast cancer was increased only for recent users
while after more than 5 years of nonuse the risk was not signifi-
cantly elevated (SIR = 1.38 versus SIR = 0.49). 
There was no sign of interaction between a previous use of oral
contraceptives and later HRT use as oral contraceptive use for
more than 2 years followed by more than 4 years use of HRT
yielded an SIR of 1.79 (95% CI 1.04–2.87). 
DISCUSSION 
The main result of the present investigation is the finding of an
increased risk of breast cancer after prolonged HRT use in a popu-
lation-based cohort. After more than 4 years of exposure a SIR of
1.92 was noted. This risk is higher and appears after a shorter
exposure than noted in most other investigations including the
collaborative meta-analysis (Collaborative Group on Hormonal
Factors in Breast Cancer, 1997). This could be due to the extensive
use in south Sweden of combined hormone preparations, given
that in some recent investigations a higher breast cancer risk has
been seen for combined use than for oestrogen only preparations
(Magnusson et al, 1999; Ross et al, 2000; Schairer et al, 2000).
That oestrogen-only preparations were not frequently used is
further substantiated by the finding of a low endometrial cancer
risk. The risk of breast cancer in our study was independent of
known risk factors of breast cancer and did not interact with a
family history of breast cancer among first degree relatives.
Although we did not analyse brand of HRT used, the predominant
prescription in Sweden has been HRT containing both oestrogen
and progestins given either as continuous or sequential therapy
Table 1 Duration of hormone replacement therapy in relation to observed and expected
number of breast cancer, SIR (95% CI), number of individuals and person years 
Duration (months) OBS SIR 95% CI n Person years 
0, or never users 345 1.06 0.95–1.18 26238 202 197 
1–48 44 1.18 0.85–1.58 2005 15 049 
48–120 33 1.92 1.32–2.70 851 6349 
120+ 12 1.36 0.70–2.37 414 3016 
Table 2 Hormone replacement therapy (HRT) in relation to a family history of breast cancer (first
degree relative with breast cancer) 
HRT use (ever use) OBS SIR 95% CI n Person years 
Family history of breast cancer 10 2.20 1.06–4.05 230 1723.5 
No family history of breast cancer 84 1.31 1.04–1.62 3341 24953.2 
Never HRT use
Family history of breast cancer 35 1.77 1.24–2.47 1385 10 598 
No family history of breast cancer 304 1.02 0.91–1.14 24 460 188 659
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while monotherapy with oestrogens has been reserved for women
who have had a prior hysterectomy. Whether 10 years or more of
HRT use confers an even higher breast cancer risk can at present
not be addressed using this cohort given that, as of yet, too few
women have been exposed to HRT for such a duration. 
In line with the data from the Collaborative Group on Hormonal
Factors in Breast Cancer (Collaborative Group on Hormonal
Factors in Breast Cancer, 1997), we found that recent HRT use
conferred an increased risk of breast cancer while women who had
not used HRT for at least 5 years prior to diagnosis were at no
increased risk. 
Our study can not confirm that HRT confers an especially high
risk of breast cancer to women who have previously used oral
contraceptives (Brinton et al, 1998). 
It is interesting to note that although breast cancer incidence was
increased no overall increase in cancer incidence was noted after
HRT use. It thus seems that HRT use increases tumour incidence
mainly for breast cancer, but this increase is counteracted by a
lower incidence of other tumours. 
Compared with another Swedish cohort investigation of HRT
use the present cohort investigation has the advantage of retrieving
the HRT information by direct interviews and not by prescriptions
filled at pharmacies (Persson et al, 1997). The recall of the expo-
sure was further aided by time calendar and charts of brands
prescribed in Sweden. Furthermore the present cohort is popula-
tion based and not limited to the use of certain pharmacies, hospi-
tals or attending mammography units. 
There is a possibility that the hazard ratio in the within cohort
comparison is underestimated as women, who in the base-line
questionnaire stated never use, may have become users of HRT
during the follow-up time. The extent of such an underestimate
will be assessed after completion of an on-going reinterview of the
cohort. Further, the importance of different types of HRT will in a
future study be addressed by comparing questionnaire data with
hospital record information. 
In conclusion our investigation confirms a rather high risk for
breast cancer after at least 4 years of HRT use. The absolute risk
seems to be independent of family history of breast cancer. The
overall cancer incidence is not increased compared to the expected
rate in HRT users. No increased risk is seen in women after 5 years
of non-use. 
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